Diplomat Pharmacy (DPLO) Position Increased by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. raised its position in Diplomat Pharmacy (NYSE:DPLO) by 27.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,655 shares of the company’s stock after purchasing an additional 3,550 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Diplomat Pharmacy were worth $334,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Advisors Preferred LLC purchased a new position in shares of Diplomat Pharmacy during the fourth quarter worth approximately $162,000. SG Americas Securities LLC purchased a new position in shares of Diplomat Pharmacy during the third quarter worth approximately $191,000. Fox Run Management L.L.C. purchased a new position in shares of Diplomat Pharmacy during the fourth quarter worth approximately $244,000. ETRADE Capital Management LLC purchased a new position in shares of Diplomat Pharmacy during the fourth quarter worth approximately $276,000. Finally, D.A. Davidson & CO. purchased a new position in shares of Diplomat Pharmacy during the fourth quarter worth approximately $278,000. 63.73% of the stock is currently owned by institutional investors.

How to Become a New Pot Stock Millionaire

A number of equities analysts have recently commented on the stock. Barclays assumed coverage on shares of Diplomat Pharmacy in a research report on Thursday, March 8th. They set an “overweight” rating and a $27.00 target price on the stock. Deutsche Bank raised shares of Diplomat Pharmacy from a “hold” rating to a “buy” rating in a research report on Friday, March 2nd. Needham & Company LLC set a $28.00 target price on shares of Diplomat Pharmacy and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Wells Fargo reissued a “market perform” rating and set a $25.00 price objective (up from $21.50) on shares of Diplomat Pharmacy in a report on Tuesday, February 27th. Finally, Leerink Swann set a $30.00 price objective on shares of Diplomat Pharmacy and gave the company a “buy” rating in a report on Tuesday, February 27th. Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $25.38.

In other Diplomat Pharmacy news, Director Philip R. Hagerman sold 2,150,000 shares of the firm’s stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $20.65, for a total value of $44,397,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 30.20% of the company’s stock.

Shares of DPLO stock opened at $21.47 on Wednesday. The company has a market cap of $1,433.98, a P/E ratio of 25.56 and a beta of 1.32. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.66 and a current ratio of 0.97. Diplomat Pharmacy has a 52-week low of $14.23 and a 52-week high of $27.78.

Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings data on Monday, February 26th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.16 by $0.02. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.17 billion. Diplomat Pharmacy had a net margin of 0.35% and a return on equity of 8.89%. Diplomat Pharmacy’s revenue was up .9% compared to the same quarter last year. During the same period last year, the company posted $0.08 earnings per share. sell-side analysts anticipate that Diplomat Pharmacy will post 0.93 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://weekherald.com/2018/04/18/diplomat-pharmacy-dplo-position-increased-by-envestnet-asset-management-inc.html.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply